Published on
January 3, 2024
- 12:00 GMT
SLAM Bio Secures Early Investment for First-in-Class Antibody Programs
THOUSAND OAKS, CA, UNITED STATES, January 3, 2024 /EINPresswire.com/ -- SLAM BioTherapeutics, Inc., a promising biotechnology company, dedicated to novel oncology and autoimmune therapies, announces a seed round of over $8 Million to advance its …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
